Published in the Red Journal, this study identified patients who benefit most from PBT in terms of predicted 30-year absolute mortality risks (AMR30) from radiation-related cardiovascular disease (CVD) and second cancers (SC). Eighty patients with supradiaphragmatic HL treated with PBT were re-planned using optimal photon-RT. Doses and AMR30 from CVD and SC of the lung, breast and esophagus were compared for all patients. This study found that the predicted benefit of PBT is not universal and is limited to certain categories of lymphoma patients with lower mediastinal or axillary disease.